11 results
8-K
EX-1.1
BGLC
BioNexus Gene Lab Corp
24 Jul 23
BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:28pm
taxes on resale of any of the Shares held by them, and any advertising expenses connected with any offers they may make.
(d) Company Reimbursement … in accordance with such request, or shall not have disputed in good faith the Indemnified Person’s entitlement to such reimbursement, prior to the date
424B4
BGLC
BioNexus Gene Lab Corp
21 Jul 23
Prospectus supplement with pricing info
3:37pm
of the government investigation described below, potential and pending litigation, potential pay or recoupments of reimbursement amounts, and other contingencies … ;
the commercial success of BioNexus’ products;
BioNexus’ ability to obtain more extensive coverage and reimbursement for BGL’ tests and therapeutic
8-K
EX-10.4
rovrllo
15 Oct 19
Entry into a Material Definitive Agreement
4:00pm
- Prev
- 1
- Next